We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Vitamin D Supplementation on Hemoglobin A1c in Patients With Uncontrolled Type 2 Diabetes Mellitus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00985361
Recruitment Status : Completed
First Posted : September 28, 2009
Last Update Posted : May 6, 2010
Sponsor:
Information provided by:

Study Description
Brief Summary:
The purpose of this study is to determine if daily supplementation with 2000 International Units of Vitamin D will improve hemoglobin A1c in uncontrolled type 2 diabetics.

Condition or disease Intervention/treatment
Type 2 Diabetes Mellitus Dietary Supplement: Vitamin D3 2000 international units daily Dietary Supplement: Vitamin C 500mg daily

Detailed Description:
Vitamin D is typically understood to support musculoskeletal health when administered concomitantly with calcium. A number of recent studies suggest, however, that this important nutrient may play a significant role in many pathophysiological processes, including diabetes mellitus. With the prevalence of diabetes mellitus ever increasing, novel mechanisms for controlling blood glucose and hemoglobin A1c are being sought to help prevent the costly and debilitating complications of this chronic disease.

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 37 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Effect of Vitamin D Supplementation on Hemoglobin A1c in Patients With Uncontrolled Type 2 Diabetes Mellitus
Study Start Date : October 2009
Primary Completion Date : March 2010
Study Completion Date : March 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Vitamin D
Drug Information available for: Vitamin D
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: Vitamin D 2000 international units daily Dietary Supplement: Vitamin D3 2000 international units daily
Vitamin D3 2000 international unit tablets once daily for 3 months
Active Comparator: Vitamin C 500mg daily Dietary Supplement: Vitamin C 500mg daily
Vitamin C 500mg tablets once daily for 3 months


Outcome Measures

Primary Outcome Measures :
  1. Hemoglobin A1c [ Time Frame: 3 months ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   21 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Type 2 diabetes mellitus
  • Hemoglobin A1c >7% measured in the 3 months prior to randomization
  • Age 21 to 75 years

Exclusion Criteria:

  • Renal insufficiency (defined as CrCl <30mL/min)
  • Gestational diabetes
  • Malabsorption syndrome
  • Patients taking vitamin D supplements at doses >400 international units daily
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00985361


Locations
United States, Ohio
Flower Hospital Family Medicine Residency
Sylvania, Ohio, United States, 43560
Center for Health Services
Toledo, Ohio, United States, 43606
Toledo Hospital Family Medicine Residency
Toledo, Ohio, United States, 43606
Sponsors and Collaborators
ProMedica Health System
Investigators
Principal Investigator: Mate M Soric, PharmD ProMedica Health System
More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Mate Soric, ProMedica
ClinicalTrials.gov Identifier: NCT00985361     History of Changes
Other Study ID Numbers: 09-055
First Posted: September 28, 2009    Key Record Dates
Last Update Posted: May 6, 2010
Last Verified: October 2009

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Vitamins
Vitamin D
Ergocalciferols
Cholecalciferol
Ascorbic Acid
Micronutrients
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents
Antioxidants
Molecular Mechanisms of Pharmacological Action
Protective Agents